دورية أكاديمية
Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review
| العنوان: | Successful Treatment of Systemic Lupus Erythematosus-Associated Thrombocytopenia with Eltrombopag: A Report of Two Cases and Literature Review |
|---|---|
| المؤلفون: | UlutaÅŸ, F., Ök, Z.D., Çobankara, V., Karasu, U. |
| بيانات النشر: | Greek Rheumatology Society and Professional Association of Rheumatologists |
| سنة النشر: | 2022 |
| المجموعة: | Pamukkale University Repository / Pamukkale Üniversitesi Açık Erişim Arşivi |
| مصطلحات موضوعية: | Anti-thrombopoietin receptor, Eltrombopag, Intravenous immunoglobulin, Systemic lupus erythematosus, Thrombocytopenia, acetylsalicylic acid, alpha 1 microglobulin, antinuclear antibody, azathioprine, cardiolipin antibody, cyclophosphamide, cyclosporine, double stranded DNA antibody, glucocorticoid, hydroxychloroquine, immunoglobulin, mycophenolate mofetil, rituximab, adult, arthritis, Article, case report, clinical article, disease association, drug dose titration, drug megadose, female, human, human cell, malar rash |
| الوصف: | Thrombocytopenia is one of the common haematological manifestations, occurring in 7% to 30% of systemic lupus erythematosus (SLE) patients. Immune thrombocytopenia (ITP) may occur in variable pathways as a result of cross-reacting antibodies or immune complexes that bind to platelet receptors, or infection of progenitor megakaryocytes, and decreased production of thrombopoietin (TPO). It was shown that the vast majority of SLE patients with thrombocytopenia had increased levels of anti-glycoprotein IIb/IIIa (anti-GPIIb/IIIa) or anti-thrombopoietin receptor (anti-TPOR). Eltrombopag is a thrombopoietin receptor agonist that binds to the transmembrane portion of the surface receptor and induces maturation of megakaryocytes and production of platelets. Herein, we report two SLE patients with severe thrombocytopenia who are also refractory to both intravenous immunoglobulin (IVIG), rituximab, and splenectomy. Ultimately, they successfully treated with eltrombopag without any complication. Eltrombopag worked well and their platelet counts increased above 200,000/ mm3 only two weeks later © This work is licensed under a Creative Commons Attribution 4.0 International License |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2459-3516 |
| العلاقة: | Mediterranean Journal of Rheumatology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.31138/mjr.33.4.444Test; https://hdl.handle.net/11499/50614Test; 33; 444; 448; 2-s2.0-85146660428 |
| DOI: | 10.31138/mjr.33.4.444 |
| الإتاحة: | https://doi.org/10.31138/mjr.33.4.444Test https://hdl.handle.net/11499/50614Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.41146BA |
| قاعدة البيانات: | BASE |
| تدمد: | 24593516 |
|---|---|
| DOI: | 10.31138/mjr.33.4.444 |